Keros Therapeutics, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Keros announced it will receive a $20 million development milestone payment from Takeda following first patient dosing in the ELRiSE MF Phase 3 trial of elritercept for myelofibrosis. This is one of several milestones under the January 2025 global license agreement with Takeda, under which Keros received a $200 million upfront payment and is eligible for up to $1.1 billion in additional development, commercial and sales milestones, plus tiered royalties. Keros plans to distribute 25% of net proceeds (~$5 million) to stockholders.
Why this rating
Modest cash inflow (4.4% of market cap) confirms partnership progress but is routine milestone execution under existing deal, not transformational.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.